Selected research
Industry Research
AI Clinical Trial Imaging Industry Research Report 2026
Market perspective
The global AI Clinical Trial Imaging market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the AI Clinical Trial Imaging market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the AI Clinical Trial Imaging market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the AI Clinical Trial Imaging market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of AI Clinical Trial Imaging include AICure, Brainomix, Clario, Lantern Pharma, Median, Neuroute, Owkin, PathAI and Quibim, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global AI Clinical Trial Imaging market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to AI Clinical Trial Imaging.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
AI Clinical Trial Imaging Market by Company
AICure
Brainomix
Clario
Lantern Pharma
Median
Neuroute
Owkin
PathAI
Quibim
Saama
Spectral
VIDA
Voiant
AI Clinical Trial Imaging Segment by Type
Based on Machine Learning
Based on Deep Learning
Others
AI Clinical Trial Imaging Segment by Application
Telemedicine
Diagnostic Assistance
Clinical Decision Support
Others
AI Clinical Trial Imaging Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Clinical Trial Imaging market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI Clinical Trial Imaging and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Clinical Trial Imaging.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of AI Clinical Trial Imaging companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Based on Machine Learning
- Based on Deep Learning
- Others
Applications
- Telemedicine
- Diagnostic Assistance
- Clinical Decision Support
- Others
Companies covered
- AICure
- Brainomix
- Clario
- Lantern Pharma
- Median
- Neuroute
- Owkin
- PathAI
- Quibim
- Saama
- Spectral
- VIDA
- Voiant
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 AI Clinical Trial Imaging by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Based on Machine Learning
- 2.2.3 Based on Deep Learning
- 2.2.4 Others
- 2.3 AI Clinical Trial Imaging by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Telemedicine
- 2.3.3 Diagnostic Assistance
- 2.3.4 Clinical Decision Support
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 AI Clinical Trial Imaging Breakdown Data by Type
- 3.1 Global AI Clinical Trial Imaging Historic Market Size by Type (2021-2026)
- 3.2 Global AI Clinical Trial Imaging Forecasted Market Size by Type (2027-2032)
4 AI Clinical Trial Imaging Breakdown Data by Application
- 4.1 Global AI Clinical Trial Imaging Historic Market Size by Application (2021-2026)
- 4.2 Global AI Clinical Trial Imaging Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global AI Clinical Trial Imaging Market Perspective (2021-2032)
- 5.2 Global AI Clinical Trial Imaging Growth Trends by Region
- 5.2.1 Global AI Clinical Trial Imaging Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 AI Clinical Trial Imaging Historic Market Size by Region (2021-2026)
- 5.2.3 AI Clinical Trial Imaging Forecasted Market Size by Region (2027-2032)
- 5.3 AI Clinical Trial Imaging Market Dynamics
- 5.3.1 AI Clinical Trial Imaging Industry Trends
- 5.3.2 AI Clinical Trial Imaging Market Drivers
- 5.3.3 AI Clinical Trial Imaging Market Challenges
- 5.3.4 AI Clinical Trial Imaging Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top AI Clinical Trial Imaging Players by Revenue
- 6.1.1 Global Top AI Clinical Trial Imaging Players by Revenue (2021-2026)
- 6.1.2 Global AI Clinical Trial Imaging Revenue Market Share by Players (2021-2026)
- 6.2 Global AI Clinical Trial Imaging Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of AI Clinical Trial Imaging Head Office and Area Served
- 6.4 Global AI Clinical Trial Imaging Players, Product Type & Application
- 6.5 Global AI Clinical Trial Imaging Manufacturers Established Date
- 6.6 Global AI Clinical Trial Imaging Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America AI Clinical Trial Imaging Market Size (2021-2032)
- 7.2 North America AI Clinical Trial Imaging Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America AI Clinical Trial Imaging Market Size by Country (2021-2026)
- 7.4 North America AI Clinical Trial Imaging Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe AI Clinical Trial Imaging Market Size (2021-2032)
- 8.2 Europe AI Clinical Trial Imaging Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe AI Clinical Trial Imaging Market Size by Country (2021-2026)
- 8.4 Europe AI Clinical Trial Imaging Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific AI Clinical Trial Imaging Market Size (2021-2032)
- 9.2 Asia-Pacific AI Clinical Trial Imaging Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific AI Clinical Trial Imaging Market Size by Country (2021-2026)
- 9.4 Asia-Pacific AI Clinical Trial Imaging Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America AI Clinical Trial Imaging Market Size (2021-2032)
- 10.2 South America AI Clinical Trial Imaging Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America AI Clinical Trial Imaging Market Size by Country (2021-2026)
- 10.4 South America AI Clinical Trial Imaging Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa AI Clinical Trial Imaging Market Size (2021-2032)
- 11.2 Middle East & Africa AI Clinical Trial Imaging Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa AI Clinical Trial Imaging Market Size by Country (2021-2026)
- 11.4 Middle East & Africa AI Clinical Trial Imaging Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AICure
- 12.1.1 AICure Company Information
- 12.1.2 AICure Business Overview
- 12.1.3 AICure Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.1.4 AICure AI Clinical Trial Imaging Product Portfolio
- 12.1.5 AICure Recent Developments
- 12.2 Brainomix
- 12.2.1 Brainomix Company Information
- 12.2.2 Brainomix Business Overview
- 12.2.3 Brainomix Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.2.4 Brainomix AI Clinical Trial Imaging Product Portfolio
- 12.2.5 Brainomix Recent Developments
- 12.3 Clario
- 12.3.1 Clario Company Information
- 12.3.2 Clario Business Overview
- 12.3.3 Clario Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.3.4 Clario AI Clinical Trial Imaging Product Portfolio
- 12.3.5 Clario Recent Developments
- 12.4 Lantern Pharma
- 12.4.1 Lantern Pharma Company Information
- 12.4.2 Lantern Pharma Business Overview
- 12.4.3 Lantern Pharma Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.4.4 Lantern Pharma AI Clinical Trial Imaging Product Portfolio
- 12.4.5 Lantern Pharma Recent Developments
- 12.5 Median
- 12.5.1 Median Company Information
- 12.5.2 Median Business Overview
- 12.5.3 Median Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.5.4 Median AI Clinical Trial Imaging Product Portfolio
- 12.5.5 Median Recent Developments
- 12.6 Neuroute
- 12.6.1 Neuroute Company Information
- 12.6.2 Neuroute Business Overview
- 12.6.3 Neuroute Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.6.4 Neuroute AI Clinical Trial Imaging Product Portfolio
- 12.6.5 Neuroute Recent Developments
- 12.7 Owkin
- 12.7.1 Owkin Company Information
- 12.7.2 Owkin Business Overview
- 12.7.3 Owkin Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.7.4 Owkin AI Clinical Trial Imaging Product Portfolio
- 12.7.5 Owkin Recent Developments
- 12.8 PathAI
- 12.8.1 PathAI Company Information
- 12.8.2 PathAI Business Overview
- 12.8.3 PathAI Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.8.4 PathAI AI Clinical Trial Imaging Product Portfolio
- 12.8.5 PathAI Recent Developments
- 12.9 Quibim
- 12.9.1 Quibim Company Information
- 12.9.2 Quibim Business Overview
- 12.9.3 Quibim Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.9.4 Quibim AI Clinical Trial Imaging Product Portfolio
- 12.9.5 Quibim Recent Developments
- 12.10 Saama
- 12.10.1 Saama Company Information
- 12.10.2 Saama Business Overview
- 12.10.3 Saama Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.10.4 Saama AI Clinical Trial Imaging Product Portfolio
- 12.10.5 Saama Recent Developments
- 12.11 Spectral
- 12.11.1 Spectral Company Information
- 12.11.2 Spectral Business Overview
- 12.11.3 Spectral Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.11.4 Spectral AI Clinical Trial Imaging Product Portfolio
- 12.11.5 Spectral Recent Developments
- 12.12 VIDA
- 12.12.1 VIDA Company Information
- 12.12.2 VIDA Business Overview
- 12.12.3 VIDA Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.12.4 VIDA AI Clinical Trial Imaging Product Portfolio
- 12.12.5 VIDA Recent Developments
- 12.13 Voiant
- 12.13.1 Voiant Company Information
- 12.13.2 Voiant Business Overview
- 12.13.3 Voiant Revenue in AI Clinical Trial Imaging Business (2021-2026)
- 12.13.4 Voiant AI Clinical Trial Imaging Product Portfolio
- 12.13.5 Voiant Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst